Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dynamic PET acquisition-a Quantitative Technique for Grading of Malignant Tumors and Prediction of Response to Treatment

This study has been completed.
Information provided by:
Rambam Health Care Campus Identifier:
First received: February 20, 2006
Last updated: July 28, 2010
Last verified: May 2008

To assess a quantitative kinetic model of FDG uptake measurement using PET in patients with aggressive Non-Hodgkin's lymphoma and cancer of the pancreas, malignancies with known variability in disease aggressiveness and prognosis, for optimized tailoring of the therapeutic strategy in the individual patient.

Condition Intervention Phase
Pancreatic Cancer
Device: PET-CT
Phase 0

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Dynamic FDG-PET in Aggressive Lymphoma and Pancreas Cancer

Resource links provided by NLM:

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • The impact of the imaging modality on patient management [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • patient management [ Time Frame: 10 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 70
Study Start Date: August 2006
Study Completion Date: April 2010
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with pancreatric cancer


Inclusion Criteria:

  • age>18
  • newly diagnosed untreated aggressive NHL
  • newly diagnosed untreated cancer of pancreas

Exclusion Criteria:

  • none
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00294840

Rambam Medical Center
Haifa, Israel
Sponsors and Collaborators
Rambam Health Care Campus
Principal Investigator: Ora Israel, MD Rambam Health Care Campus
  More Information

No publications provided

Responsible Party: Dr. Alex Frenkel, Rambam HealthCare Campus Identifier: NCT00294840     History of Changes
Other Study ID Numbers: PETDCTIL
Study First Received: February 20, 2006
Last Updated: July 28, 2010
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms by Site
Pancreatic Diseases processed this record on November 24, 2014